Eyenovia Inc (NQ: EYEN )
4.400 USD UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2021 Add to My Watchlist
Press releases about Eyenovia Inc
Arctic Vision Announces Addition of Novel Mydriatic Drug MydCombi™ (ARVN004) to Eyenovia Commercialization Deal
September 16, 2021
Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it will expand its exclusive license agreement with Eyenovia, Inc. (NASDAQ: EYEN) to...
From PR Newswire
Eyenovia Reports Second Quarter 2021 Financial Results
August 11, 2021
Eyenovia will participate in a July 22 Eyecelerator@ASCRS panel, entitled, “Presbyopia: Everybody gets it... but can it be fixed?”
Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
June 15, 2021
Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia
May 25, 2021
Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
April 01, 2021
Dr. Julia Haller brings experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader to her role as an Eyenovia director.
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
March 23, 2021
Eyenovia has tapped EVERSANA as exclusive distributor of its MydCombi product for pupil dilation in the U.S., pending the product's FDA approval.
Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Efficacy and Safety of its MAP™ Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasis
March 17, 2021
Eyenovia's MAP™ fixed-combination pharmaceutical for pupil dilation has been shown to be safe, effective and superior in comparative study.
Eyenovia to Participate in the 33rd Annual Roth Conference
March 10, 2021
Eyenovia Announces FDA Acceptance of the MydCombi NDA
March 02, 2021
FDA accepts Eyenovia's NDA for MydCombi, a unique fixed combination pupil dilation agent delivered with the Optejet. PDUFA date is expected 4Q 2021.
Eyenovia to Host Key Opinion Leader Webinar on Presbyopia
February 16, 2021
The webinar, “Presbyopia in Focus: Unlocking One of the Biggest Market Opportunities in Ophthalmology,” is scheduled for Monday, February 22, at 1:00pm ET
Pazanga Healthcare Communications Closes a Robust 2020 with Four New Healthcare Clients
January 28, 2021
Strategic communications agency Pazanga Health closed a record-setting year in 2020, winning four new healthcare clients in Q4 alone.
Eyenovia to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
January 26, 2021
Eyenovia consultant Dr. David Wirta will speak at the Ophthalmology Innovation Summit Presbyopia Innovation Showcase on January 28.
Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today...
Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event
January 06, 2021
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually
December 29, 2020
Eyenovia has submitted an NDA to the FDA for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent delivered by the Optejet dispenser.
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
December 16, 2020
Eyenovia has enrolled its first patients in the Phase 3 VISION-1 Study of MicroLine for the improvement in near vision in patients with presbyopia.
Eyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End
December 03, 2020
Eyenovia obtains FDA acceptance of its IND application for MicroLine, a therapy designed for improvement in near vision in patients with presbyopia.
Eyenovia Reports Third Quarter 2020 Financial Results
November 10, 2020
Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10
November 05, 2020
Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million
October 13, 2020
Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12
October 12, 2020
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, its leading global eye health business, and Eyenovia, Inc., (NASDAQ: EYEN) ("Eyenovia"), a clinical stage ophthalmic...
From PR Newswire